Corvus Gross Profit from 2010 to 2025

CRVS Stock

USD 4.17 0.14 3.25%

Corvus Pharmaceuticals Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit will likely drop to about -142.7 K in 2025. Gross Profit is the profit Corvus Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2014-12-31

Previous Quarter

-23 K

Current Value

-21 K

Quarterly Volatility

63.8 K

Yuan Drop

Covid

Check Corvus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corvus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 129.1 K, Interest Expense of 1.9 M or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.06. Corvus financial statements analysis is a perfect complement when working with Corvus Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Corvus Pharmaceuticals Correlation against competitors.

For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.

Latest Corvus Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Corvus Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Corvus Pharmaceuticals minus its cost of goods sold. It is profit before Corvus Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Corvus Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corvus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Corvus Gross Profit Regression Statistics

	Arithmetic Mean	(316,412)
	Geometric Mean	0.00
	Coefficient Of Variation	(101.88)
	Mean Deviation	283,764
	Median	(148,000)
	Standard Deviation	322,350
	Sample Variance	103.9B
	Range	847K
	R-Value	(0.32)
	Mean Square Error	99.6B
	R-Squared	0.11
	Significance	0.22
	Slope	(22,005)
	Total Sum of Squares	1.6T

Corvus Gross Profit History

	2025	-142.7 K
	2024	-135.9 K
	2023	-151 K
	2022	-367 K
	2021	-460 K
	2020	-632 K
	2019	-743 K

Other Fundumenentals of Corvus Pharmaceuticals

Gross Profit Margin

Corvus Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.78	0.75	0.71	-0.71	-0.37	0.74	-0.1	0.18	0.93	-0.08	0.13	0.39	0.07	0.58	0.24	0.06	0.02	0.11
Total Stockholder Equity	0.78		0.99	0.82	-0.76	-0.53	0.68	-0.26	-0.47	0.65	0.26	0.3	0.57	-0.05	0.77	0.09	-0.11	0.18	-0.07
Net Tangible Assets	0.75	0.99		0.86	-0.73	-0.6	0.69	-0.32	-0.49	0.62	0.22	0.39	0.64	-0.12	0.82	-0.02	-0.19	0.28	-0.18
Current Deferred Revenue	0.71	0.82	0.86		-0.4	-0.87	0.85	-0.64	-0.25	0.5	-0.18	0.65	0.82	-0.29	0.96	-0.38	-0.54	0.53	-0.5
Net Debt	-0.71	-0.76	-0.73	-0.4		-0.01	-0.35	-0.22	0.21	-0.78	-0.44	0.13	-0.09	-0.09	-0.29	-0.47	-0.41	0.17	-0.26
Retained Earnings	-0.37	-0.53	-0.6	-0.87	-0.01		-0.63	0.87	0.27	-0.09	0.41	-0.89	-0.86	0.26	-0.92	0.62	0.79	-0.8	0.76
Accounts Payable	0.74	0.68	0.69	0.85	-0.35	-0.63		-0.48	-0.01	0.57	-0.17	0.29	0.53	-0.36	0.76	-0.19	-0.36	0.16	-0.16
Short Term Investments	-0.1	-0.26	-0.32	-0.64	-0.22	0.87	-0.48		0.23	0.22	0.55	-0.83	-0.63	0.34	-0.7	0.56	0.8	-0.79	0.7
Total Liab	0.18	-0.47	-0.49	-0.25	0.21	0.27	-0.01	0.23		0.27	-0.56	-0.25	-0.31	0.13	-0.37	0.15	0.2	-0.21	0.21
Total Current Assets	0.93	0.65	0.62	0.5	-0.78	-0.09	0.57	0.22	0.27		0.14	-0.1	0.21	0.15	0.36	0.39	0.36	-0.21	0.3
Short Term Debt	-0.08	0.26	0.22	-0.18	-0.44	0.41	-0.17	0.55	-0.56	0.14		-0.49	-0.21	0.08	-0.17	0.41	0.6	-0.53	0.46
Common Stock	0.13	0.3	0.39	0.65	0.13	-0.89	0.29	-0.83	-0.25	-0.1	-0.49		0.82	-0.07	0.77	-0.65	-0.76	0.95	-0.83
Property Plant Equipment	0.39	0.57	0.64	0.82	-0.09	-0.86	0.53	-0.63	-0.31	0.21	-0.21	0.82		-0.11	0.86	-0.63	-0.67	0.76	-0.67
Net Receivables	0.07	-0.05	-0.12	-0.29	-0.09	0.26	-0.36	0.34	0.13	0.15	0.08	-0.07	-0.11		-0.23	0.47	0.44	-0.09	0.35
Capital Surpluse	0.58	0.77	0.82	0.96	-0.29	-0.92	0.76	-0.7	-0.37	0.36	-0.17	0.77	0.86	-0.23		-0.43	-0.59	0.61	-0.54
Net Invested Capital	0.24	0.09	-0.02	-0.38	-0.47	0.62	-0.19	0.56	0.15	0.39	0.41	-0.65	-0.63	0.47	-0.43		0.88	-0.69	0.88
Net Working Capital	0.06	-0.11	-0.19	-0.54	-0.41	0.79	-0.36	0.8	0.2	0.36	0.6	-0.76	-0.67	0.44	-0.59	0.88		-0.78	0.85
Capital Stock	0.02	0.18	0.28	0.53	0.17	-0.8	0.16	-0.79	-0.21	-0.21	-0.53	0.95	0.76	-0.09	0.61	-0.69	-0.78		-0.9
Long Term Investments	0.11	-0.07	-0.18	-0.5	-0.26	0.76	-0.16	0.7	0.21	0.3	0.46	-0.83	-0.67	0.35	-0.54	0.88	0.85	-0.9

Click cells to compare fundamentals

About Corvus Pharmaceuticals Financial Statements

Corvus Pharmaceuticals shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Corvus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Corvus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corvus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Gross Profit	-135.9 K	-142.7 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Corvus Stock Analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC